+357 96 030922
info@marketpublishers.com

U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/U4BACC97AA96EN.html
Date: January 2025
Pages: 130
Price: US$ 5,950.00 (Single User License)
ID: U4BACC97AA96EN

Abstracts

This report can be delivered to the clients within 3 Business Days

U.S. Pancreatic Cancer Treatment Market Growth & Trends

The U.S. pancreatic cancer treatment market is anticipated t%li%reach USD 2.01 billion by 2030 and is expected t%li%grow at a CAGR of 12.02% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.

Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due t%li%late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues t%li%be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.

Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues t%li%hamper early detection and the development of personalized treatments.

Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are als%li%playing a crucial role in addressing unmet needs in pancreatic cancer treatment.

The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively t%li%address the critical needs of patients and families affected by this devastating disease. The next decade promises t%li%reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.

U.S. Pancreatic Cancer Treatment Market Report Highlights

On the basis of type, the exocrine segment held the largest revenue share of 43.25% of the U.S. pancreatic cancer treatment market in 2024. This dominance is attributed t%li%the high prevalence of exocrine pancreatic cancer, which accounts for the majority of cases, and advancements in treatment modalities targeting this type.

Based on treatment, the chemotherapy dominated the market with a share of 43.25% and is expected t%li%maintain its lead during the forecast period. The widespread use of chemotherapy, particularly gemcitabine-based regimens and FOLFIRINOX, has been instrumental in managing pancreatic cancer, despite challenges such as resistance and side effects.

Based on distribution channel, the hospital pharmacies accounted for the largest revenue share of 46.01% in 2024 and are expected t%li%continue leading the market. This is due t%li%the critical role hospitals play in administering complex treatment regimens, coupled with the increasing number of inpatient visits for pancreatic cancer diagnosis and treatment.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 7. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: U.S. Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By Distribution Channel, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/U4BACC97AA96EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U4BACC97AA96EN.html